Ticlopidine

From Self-sufficiency
Jump to: navigation, search
Ticlopidine
File:Ticlopidine.svg
Systematic (IUPAC) name
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
Clinical data
Pregnancy
category
  • AU: B1
  • US: C (Risk not ruled out)
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability >80%
Protein binding 98%
Metabolism Hepatic
Biological half-life
  • 12 hours (single dose)
  • 4 to 5 days (after repeated dosing)
Excretion Renal and fecal
Identifiers
CAS Number 55142-85-3
ATC code B01AC05 (WHO)
PubChem CID 5472
DrugBank APRD01257
Chemical data
Formula C14H14ClNS
Molar mass 263.786 g/mol[[Script error: No such module "String".]]
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Like clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. It is used in patients in whom aspirin is not tolerated, or in whom dual antiplatelet therapy is desirable. Because it has been reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is felt to have a much lower hematologic risk. The usual dose is 250 mg twice daily by the oral route.

Action

  • Inhibits platelet aggregation by altering the function of platelet membranes by blocking ADP receptors. This prevents the conformational change of glycoprotein IIb/IIIa which allows platelet binding to fibrinogen.
  • Prolongs bleeding time.
  • Decreased incidence of stroke in high-risk patients.

Contraindications

Precautions

de:Ticlopidin

fr:Ticlopidine it:Ticlopidina pt:Ticlopidina